Fabian Model - Epigenomics Inc | 人才画像

基本信息

浏览量：46

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 129 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Application of the Parametric G-Formula to Characterizing Counterfactual Time-to-Event Disability Progression Outcomes in Multiple Sclerosis

Sean Yiu,Qing Wang,Francois Mercier,Frank Dahlke,Fabian Model

Statistics in Biosciencespp.1-27, (2024)

引用0浏览0引用

DNL310 Phase 1/2 Case Study Demonstrates Properties of Raw, Standard and Growth Scale Scores for Adaptive Behavior Scales

Natalie J. Engmann,Adam Scheller,Rupa Caprihan, Thomas Neitmann,Anna Bakardjiev,Fabian Model, Michael Ostland

MOLECULAR GENETICS AND METABOLISMno. 2 (2024)

引用0浏览0引用

Five-year Efficacy Outcomes of Ocrelizumab in Relapsing Multiple Sclerosis: A Propensity-Matched Comparison of the OPERA Studies with Other Disease-Modifying Therapies in Real-World Lines of Treatments

Erwan Muros-Le Rouzic,Yanic Heer,Sean Yiu,Viola Tozzi,Stefan Braune,Philip van Hovell,Arnfin Bergmann,Corrado Bernasconi,Fabian Model,Licinio Craveiro

Journal of Central Nervous System Disease (2024)

引用0浏览0WOS引用

Recurrent Disability Progression Endpoints in Multiple Sclerosis Clinical Trials

Alexandra Buehler,Marcel Wolbers,Fabian Model,Qing Wang,Shibeshih Belachew,Marianna Manfrini,Johannes Lorscheider,Ludwig Kappos,Jan Beyersmann

MULTIPLE SCLEROSIS JOURNAL（2023）

引用1浏览0WOS引用

Association of Higher Ocrelizumab Exposure with Reduced Disability Progression in Multiple Sclerosis

Stephen L. Hauser,Amit Bar-Or,Martin S. Weber,Heidemarie Kletzl,Andreas Guenther,Marianna Manfrini,Fabian Model,Francois Mercier,Claire Petry, Qing Wing,Harold Koendgen,Terence Smith,Ludwig Kappos

Neurology Neuroimmunology & Neuroinflammation（2023）

引用5浏览0WOS引用

Estimating drug concentration-response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes

Sean Yiu,Qing Wang,Francois Mercier,Marianna Manfrini,Harold Koendgen,Heidemarie Kletzl,Fabian Model

Statistical methods in medical researchno. 12 (2023): 2440-2454

引用0浏览0WOS引用

Interim Analysis of Key Clinical Outcomes from a Phase 1/2 Study of Weekly Intravenous DNL310 (Brain-Penetrant Enzyme Replacement Therapy) in MPS II

Joseph Muenzer,Barbara K. Burton,Paul Harmatz,Deepa Rajan,Simon A. Jones, Hannerieke . J. P. van den Hout,John Mitchell, Katia Meirelles,Natalie Engmann,Adam Scheller,Rupa Caprihan,Akhil Bhalla,Tony Hung, Jason Nachtigall,Imanol Zubizarreta, Sam Lu,Yuda Zhu,Peter Chin,Matt D. Troyer,Carole Ho,Wei Dong,Fabian Model

Molecular Genetics and Metabolism（2023）

引用0浏览0引用

COMPASS, a Double-Blinded Randomized Phase 2/3 Study of the Efficacy and Safety of Intravenous DNL310 (Brain-Penetrant Enzyme Replacement Therapy) in MPS II

Jose Alcantara Rodriguez,Jeff Harris, Peter Cygon,Yuda Zhu,Natalie Engmann,Simona Costanzo,Fabian Model, Wei Dong,Carole Ho,Peter Chin

Molecular Genetics and Metabolism（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn